Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes

M. J. Thomason; H. M. Colhoun; S. J. Livingstone; M. I. Mackness; D. J. Betteridge; P. N. Durrington; G. A. Hitman; H. A. W. Neil; J. H. Fuller; CARDS Investigators

doi:10.1111/j.1464-5491.2004.01401.x

Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes

M. J. Thomason
, H. M. Colhoun
, S. J. Livingstone
, M. I. Mackness
, D. J. Betteridge
, P. N. Durrington
, G. A. Hitman
, H. A. W. Neil
, J. H. Fuller
, CARDS Investigators

Research output: Contribution to journal › Article › peer-review

20 Citations (Scopus)

Abstract

To describe baseline characteristics of patients in the Collaborative AtoRvastatin Diabetes Study (CARDS), a randomized, placebo-controlled trial of lipid lowering with atorvastatin 10 mg daily for the primary prevention of major cardiovascular events in patients with Type 2 diabetes.

Original language	English
Pages (from-to)	901-905
Number of pages	5
Journal	Diabetic Medicine
Volume	21
Issue number	8
DOIs	https://doi.org/10.1111/j.1464-5491.2004.01401.x
Publication status	Published - Aug 2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1111/j.1464-5491.2004.01401.x

Cite this

Thomason, M. J., Colhoun, H. M., Livingstone, S. J., Mackness, M. I., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A. W., Fuller, J. H., & CARDS Investigators (2004). Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. Diabetic Medicine, 21(8), 901-905. https://doi.org/10.1111/j.1464-5491.2004.01401.x

@article{aac0303a1ace457ea919f60b92f195e1,

title = "Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes",

abstract = "To describe baseline characteristics of patients in the Collaborative AtoRvastatin Diabetes Study (CARDS), a randomized, placebo-controlled trial of lipid lowering with atorvastatin 10 mg daily for the primary prevention of major cardiovascular events in patients with Type 2 diabetes.",

author = "Thomason, \{M. J.\} and Colhoun, \{H. M.\} and Livingstone, \{S. J.\} and Mackness, \{M. I.\} and Betteridge, \{D. J.\} and Durrington, \{P. N.\} and Hitman, \{G. A.\} and Neil, \{H. A. W.\} and Fuller, \{J. H.\} and \{CARDS Investigators\}",

year = "2004",

month = aug,

doi = "10.1111/j.1464-5491.2004.01401.x",

language = "English",

volume = "21",

pages = "901--905",

journal = "Diabetic Medicine",

issn = "0742-3071",

publisher = "Wiley-Blackwell",

number = "8",

}

TY - JOUR

T1 - Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes

AU - Thomason, M. J.

AU - Colhoun, H. M.

AU - Livingstone, S. J.

AU - Mackness, M. I.

AU - Betteridge, D. J.

AU - Durrington, P. N.

AU - Hitman, G. A.

AU - Neil, H. A. W.

AU - Fuller, J. H.

AU - CARDS Investigators

PY - 2004/8

Y1 - 2004/8

N2 - To describe baseline characteristics of patients in the Collaborative AtoRvastatin Diabetes Study (CARDS), a randomized, placebo-controlled trial of lipid lowering with atorvastatin 10 mg daily for the primary prevention of major cardiovascular events in patients with Type 2 diabetes.

AB - To describe baseline characteristics of patients in the Collaborative AtoRvastatin Diabetes Study (CARDS), a randomized, placebo-controlled trial of lipid lowering with atorvastatin 10 mg daily for the primary prevention of major cardiovascular events in patients with Type 2 diabetes.

U2 - 10.1111/j.1464-5491.2004.01401.x

DO - 10.1111/j.1464-5491.2004.01401.x

M3 - Article

C2 - 15270795

SN - 0742-3071

VL - 21

SP - 901

EP - 905

JO - Diabetic Medicine

JF - Diabetic Medicine

IS - 8

ER -

Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this